Probiotic Enterococcus faecium CRL 183 Inhibits Candida albicans Biofilm In Vitro

Candida albicans is the most prevalent fungal microorganism of human microbiota and one of the few fungi capable of causing diseases in humans, depending on the host’s immune defense capacity. The similarity between fungal and host cells promotes several adverse effects during antifungal pharmacotherapy, and antimicrobial resistance increase is a major concern. Therefore, the search for alternative treatments and prevention strategies is urgent. In this context, probiotic bacteria, such as the strain Enterococcus faecium CRL 183, seem to be a viable alternative with its benefits to the immune system, activity against pathogens, and safety use well-documented through in vitro, in vivo, and clinical studies. Thus, this study aimed to evaluate if this probiotic strain prevents C. albicans ATCC 90028 biofilm colonization in vitro. To test the anti-Candida activity of the probiotic strain E. faecium CRL 183, we combined polymicrobial biofilms (C. albicans + E. faecium) with different proportions of fungi: a probiotic was formed (1:1, 1:10, 1:100) during the formation (24 h) and maturation (48 h) periods of the biofilm. The results show that E. faecium established itself with C. albicans in polymicrobial biofilms without losing its cellular viability. The probiotic strain significantly antagonized (p < 0.0001) C. albicans biofilm formation (up to 99.9% reduction in 24 h) and maturation (up to 99.43% reduction in 48 h). According to these results, E. faecium CRL183 may be a promising resource to prevent the formation of fungal biofilms.